Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a…

By A. Schneeweiss, S. Chia, T. Hickish, Vernon Harvey, A. Eniu, R. Hegg, C. Tausch, J. Seo, Y. Tsai, J. Ratnayake and 3 more. Annals of Oncology, 2013

1,185 citations recorded by the source corpus.

Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/6114196a3c6bf7719d2c6c755f5a6c7a6d78ae5a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Goldhirsch
2. A. Coates
3. R. Gelber
4. B. Thürlimann
5. H. Senn
6. M. Piccart-Gebhart
7. M. Gnant
8. Eric P. Winer

Citations in the corpus

• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “consistently higher clinical response (pCR) to neoadjuvant therapies for the hormone receptornegative cohort [47, 48].”